|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||May 01, 2013|
|Effective date (End):||April 30, 2014|
|Field of knowledge:||Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology|
|Principal Investigator:||José Carlos Nicolau|
|Grantee:||Beatriz Tonon Freire|
|Home Institution:||Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil|
Clopidogrel is the medication of choice, associated with acetylsalicylic acid (ASA), on the medical therapy of patients suffering of Acute Coronary Syndromes, and also on those submitted to percutaneous coronary intervention with stents. Despite this, several studies have demonstrated a great variability in individual response to the drug, with special interest in drug interaction with the proton pump inhibitors and the polymorphisms of the cytochrome CYP2C19. The ideal method to evaluate this effect is not yet stablished, although there is great popularity of the VerifyNow® because it is a point of care assay. So, the end-point of this study will be the comparison between VerifyNow® and two other methods of platelet aggregability evaluation: impedance aggregometry and PFA-100. The sample size include 100 (one hundred) subjects, consisting of patients with chronic coronary artery disease taking ASA and clopidogrel. The blood samples will be withdrawn in three moments - visit 1: patients only on ASA; visit 2: ASA with clopidogrel; and visit 3: clopdiogrel with ranitidin or omeprazole (in a double-blind design).